Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing small molecule kinase inhibitors for the treatment of serious diseases. The company leverages its proprietary drug discovery platform targeting kinase pathways. Specific pipeline products and therapeutic areas are referenced in the filing but detailed descriptions appear in sections not fully included in the provided text.
expected 2026-11-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126371 | EDGAR | 104K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046096 | EDGAR | 84K words |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037160 | EDGAR | 98K words |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011133 | EDGAR | 102K words |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005203 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001564590-21-016996 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-344707 | EDGAR | 25K words |
| 2025-11-14 | 2025-09-30 | 0001193125-25-283169 | EDGAR | 29K words |
| 2025-08-14 | 2025-06-30 | 0001193125-25-180899 | EDGAR | 26K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071635 | EDGAR | 21K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126766 | EDGAR | 21K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097022 | EDGAR | 23K words |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060579 | EDGAR | 19K words |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063713 | EDGAR | 20K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042389 | EDGAR | 19K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021974 | EDGAR | 19K words |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025011 | EDGAR | 19K words |
| 2022-08-12 | 2022-06-30 | 0000950170-22-017140 | EDGAR | 17K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-08 | 0001193125-26-385293 | EDGAR | 4K words |
| 2026-08-26 | 0001193125-26-368296 | EDGAR | 1K words |
| 2026-08-11 | 0001193125-26-344623 | EDGAR | 4K words |
| 2026-07-29 | 0001193125-26-323651 | EDGAR | 8K words |
| 2026-07-23 | 0001193125-26-313400 | EDGAR | 1K words |
| 2026-07-14 | 0001193125-26-302580 | EDGAR | 1K words |
| 2026-03-26 | 0001193125-26-126322 | EDGAR | 3K words |
| 2025-12-19 | 0001193125-25-326916 | EDGAR | 1K words |
| 2025-11-21 | 0001193125-25-291443 | EDGAR | 28K words |
| 2025-11-20 | 0001193125-25-289768 | EDGAR | 4K words |
124 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001750149 |
| Ticker | IKT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.inhibikase.com |
| Listed | 2020-12-23 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IKT (~200 tokens, structured JSON with cryptographic provenance)